<DOC>
	<DOCNO>NCT02268136</DOCNO>
	<brief_summary>The objective ot present study obtain information safety , tolerability preliminary pharmacokinetics BIII 890 CL single intravenous administration increase dos healthy male volunteer .</brief_summary>
	<brief_title>Increasing Dose Tolerance Study Healthy Male Volunteers After Administration BIII 890 CL</brief_title>
	<detailed_description />
	<criteria>Healthy male subject determine result screen Age ≥ 21 ≤ 50 year Broca index ≥ 20 % ≤ + 20 % Signed write informed consent accordance Good Clinical Practice local legislation Results medical examination , laboratory test electrocardiogram recording judge clinical investigator differ significantly normal clinical value Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Volunteers diseases central nervous system ( epilepsy ) , central nervous system trauma medical history psychiatric disorder neurological disorder Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( ≥ 24 hour ) within last month less ten halflives respective drug enrolment study Intake drug might influence result trial week previous start study Participation another study investigational drug within last two month precede study Smokers ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Volunteers able refrain smoking study day Alcohol abuse ( 60 g/day ) Drug abuse Participation excessive physical activity ( e.g . competitive sport ) within last week study Blood donation ( ≥ 100 ml ) within last 4 week</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>